Chemotherapy (CHT) adjuvant strategies and reasons for choice in breast cancer (BC) patients (pts): results from the national oncological research observatory on adjuvant therapy (NORA)

被引：0
|
作者：
Mustacchi, G. [1 ]
Cazzaniga, M. [1 ]
Pronzato, P. [1 ]
Di Costanzo, F. [1 ]
Floriani, I. [1 ]
De Matteis, A. [1 ]
机构：
[1] Univ Trieste, Trieste, Italy
来源：
EJC SUPPLEMENTS | 2004年 / 2卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(04)90665-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
62
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [41] Tumor characteristics, treatment modalities and clinical outcome in breast cancer (BC) patients (PTS) with 10 or more positive nodes. Results from the NORA study
    Cazzaniga, M. E.
    Mustacchi, G.
    Pronzato, P.
    Di Costanzo, F.
    De Matteis, A.
    Rulli, E.
    Falcone, A.
    Manente, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI8 - XI9
  • [42] What do adjuvant and metastatic breast cancer patients (BC) expect from their doctors? Final results of a german survey in 617 patients.
    Oskay-Oezcelik, G.
    Lehmacher, W.
    Mirz, R.
    Christ, H.
    Kaufmann, M.
    Bamberg, M.
    Werner, L.
    Wallwiener, D.
    Overkamp, F.
    Hindenburg, H. J.
    Sehouli, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 321S - 321S
  • [43] Prognostic value and response to chemotherapy of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (PTS) included in phase III trials of adjuvant therapy
    Trujillo, Rafael
    Gallego, E.
    Marquez, A.
    Ribelles, R.
    Perez, D.
    Quero, C.
    Medina, A.
    Olmos, D.
    Vicioso, L.
    Alba, E.
    ANNALS OF ONCOLOGY, 2007, 18 : 166 - 166
  • [44] Prognostic value and response to chemotherapy of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (pts) included in phase III trials of adjuvant therapy
    Trujillo, R.
    Gallego, E.
    Marquez, A.
    Ribelles, N.
    Perez, D.
    Quero, C.
    Medina, A.
    Jurado, J. M.
    Olmos, D.
    Alba, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 189 - 189
  • [45] RANDOMIZED ADJUVANT TRIAL TO EVALUATE THE ADDITION OF TAMOXIFEN AND PSK TO CHEMOTHERAPY IN PATIENTS WITH PRIMARY BREAST-CANCER - 5-YEAR RESULTS FROM THE NISHI-NIPPON GROUP OF THE ADJUVANT CHEMOENDOCRINE THERAPY FOR BREAST-CANCER ORGANIZATION
    TOI, M
    HATTORI, T
    AKAGI, M
    INOKUCHI, K
    ORITA, K
    SUGIMACHI, K
    DOHI, K
    NOMURA, Y
    MONDEN, Y
    HAMADA, Y
    MORIMOTO, T
    OGAWA, N
    CANCER, 1992, 70 (10) : 2475 - 2483
  • [46] Prospective evaluation of factors associated with delayed chemotherapy-induced nausea and emesis (CINE) in patients (pts) with breast cancer (BC) receiving. adjuvant anthracycline-based chemotherapy (ABCT)
    Andrade, D. A.
    Carcano, F. M.
    Teixeira, M. R.
    Gomes, J. C.
    Schroeter, D.
    Nunes, J. S.
    Souza, F. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage II/III rectal cancer treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN) analysis
    Khrizman, P.
    Niland, J. C.
    ter Veer, A.
    Milne, D.
    Dunn, K. Bullard
    Carson, W. E.
    Engstrom, P. F.
    Shibata, S.
    Skibber, J. M.
    Weiser, M. R.
    Schrag, D.
    Benson, A. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study
    Hurria, A.
    Magnuson, A.
    Gross, C. P.
    Tew, W. P.
    Klepin, H. D.
    Wildes, T. M.
    Muss, H. B.
    Dotan, E.
    Freedman, R.
    O'Connor, T.
    Dale, W.
    Cohen, H. J.
    Katheria, V.
    Arsenyan, A.
    Levi, A.
    Kim, H.
    Sun, C-L
    CANCER RESEARCH, 2019, 79 (04)
  • [49] ACUTE TOXICITY DURING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER - THE NATIONAL-SURGICAL-ADJUVANT-BREAST-AND-BOWEL-PROJECT (NSABP) EXPERIENCE FROM 1717 PATIENTS RECEIVING SINGLE AND MULTIPLE AGENTS
    GLASS, A
    WIEAND, HS
    FISHER, B
    REDMOND, C
    LERNER, H
    WOLTER, J
    SHIBATA, H
    PLOTKIN, D
    FOSTER, R
    MARGOLESE, R
    WOLMARK, N
    CANCER TREATMENT REPORTS, 1981, 65 (5-6): : 363 - 376
  • [50] Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N plus ) breast cancer (BC): The CALGB experience.
    Muss, H.
    Berry, D.
    Cirrincione, C.
    Budman, D.
    Henderson, I.
    Citron, M.
    Norton, L.
    Winer, E.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 17S - 17S
12345